Clinical trials have historically been expensive processes that rely on outdated technologies. So pharma companies are looking to leverage the latest technologies from companies like Google to reach patients in a more targeted way and get their most promising drugs approved more quickly."Clinical trials haven't changed much since the 1960's," acknowledged Rod MacKenzie, chief development officer at Pfizer. "We've been thinking about modernizing them for some time.
"From the beginning, our team on Baseline has been thinking a lot about how to bridge the gap between research and care," said Dr. Jessica Mega, Verily's chief medical officer. "And we know that it would involve working with health systems, pharma and biotech companies." The trials haven't launched yet, but Verily and its partners are exploring opportunities in cardiovascular disease, oncology, mental health, dermatology and diabetes.
In recent months, Verily has moved beyond the Baseline study, which involved partnerships with Duke and Stanford Medicine, to start enrolling even larger numbers of people in its "registry." Shore said some patients might get paid, depending on the trial, but others are incentivized to sign up for altruistic reasons or to receive health information back from Baseline. Unlike most clinical trials, Baseline is hoping to share health data with the patient rather than keeping it under lock and key.
Probably for the best
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: Reuters - 🏆 2. / 97 Прочитайте больше »